Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-05-03 Monoclonal antibody, anti-lymphocyte
| Vedolizumab Entyvio® |
|
Formulary
|
intravenous infusion 300mg vial, pre-filled pen 108mg solution for injection, pre-filled syringe 108mg solution for injection Use in high risk patients for prevention of recurrence or upon recurrance of Crohn's Disease following surgery. Moderately to severely active Crohn's disease - NICE TA352 Moderately to severely active ulcerative colitis - NICE TA342 |
 LSCMMG: Vedolizumab SC NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
|
| Vedolizumab |
|
Formulary
|
Prevention of recurrence of ulcerative colitis following surgery |
|
LSCMMG: Vedolizumab |
|
Links
- LSCMMG: Adalimumab
- LSCMMG: Certolizumab Pegol Crohn’s disease
- LSCMMG: Certolizumab Pegol Ulcerative Colitis
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Golimumab
- LSCMMG: Position Statement Use of Biosimilar Medicines
- LSCMMG: Primary Care Constipation Guidelines
- LSCMMG: Recommended Biologic Commissioning Pathway
- LSCMMG: Shared care guideline - Azathioprine
- LSCMMG: Shared care guideline - Ciclosporin
- LSCMMG: Shared care guideline - Mercaptopurine
- LSCMMG: Shared care guideline - Methotrexate
- LSCMMG: Vedolizumab
- LSCMMG: Vedolizumab SC
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
- MHRA: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies
- MHRA: Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG147: Diverticular disease: diagnosis and management
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
- NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
- NICE TA187: Crohns disease - infliximab & adalimumab
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
- NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
- NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
- NICE TA828: Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
- NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
- NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease
- NICE TA925: Mirikizumab for treating moderately to severely active ulcerative colitis
- NICE TA956: Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over
- SPS: Mesalazine monitoring